Table 1.

Dose and survival response to s50 TBG-RNAi-CK2 in mice carrying various HNSCC tumors

Dosage (mg/kg)Dosing regimenNumber of mice6-month survivalMice with tumor or metastasis signala
SCC-15 (tongue carcinoma)b
 s50 TBG-RNAi-CK250 mg/kg86c1
 s50 TBG-RNAi-CK250 mg/kg2× every 1 week840
 s50 TBG-Sense50 mg/kg811
UM-11b (laryngeal carcinoma)d
 s50 TBG-RNAi-CK250 mg/kg1× ea every 48 hour831
25 mg/kg
 s50 TBG-RNAi-CK225 mg/kg2× every 48 hour86c2
 s50 TBG-Sense25 mg/kg2× every 48 hour843
 Vehicle2× every 48 hour866
FaDu (hypopharyngeal carcinoma)
 s50 TBG-RNAi-CK210 mg/kg2× every 48 hour831
 s50 TBG-RNAi-CK20.01 mg/kg2× every 48 hour63c1
 s50 TBG-sense25 mg/kg80No survivors
 S50 TBG-sugar10 mg/kg2× every 48 hour50No survivors
 Vehicle2× every 48 hour80No survivors
  • aDetermined by luciferase imaging for all mice remaining in the survival study at 6 months as described previously (12).

  • bComparison of percentage of surviving mice with tumor or metastases, Fisher exact P = 0.118.

  • cComparison of lower to higher total s50-TBG-RNAi-CK2i dose; log-rank P < 0.001.

  • dComparison of percentage of surviving mice with tumor or metastases; Fisher exact P = 0.058.